Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effective, evidence-based infertility care.

S Daya1

  • 1Department of Obstetrics and Gynaecology, McMaster University, Hamilton, Ontario, Canada. dayas@fhs.csu.mcmaster.ca

Current Opinion in Obstetrics & Gynecology
|June 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigation of the infertile couple.

Canadian family physician Medecin de famille canadien·2011
Same author

Ectopic pregnancy resulting from transperitoneal migration of spermatozoa.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2010
Same author

WITHDRAWN: Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles.

The Cochrane database of systematic reviews·2007
Same author

WITHDRAWN: Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles.

The Cochrane database of systematic reviews·2007
Same author

WITHDRAWN: Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.

The Cochrane database of systematic reviews·2007
Same author

Non-steroidal anti-inflammatory agents, tolmetin and sulindac, inhibit liver tryptophan 2,3-dioxygenase activity and alter brain neurotransmitter levels.

Life sciences·2006
Same journal

Management of hypertensive disorders in pregnancy.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in group prenatal care research.

Current opinion in obstetrics & gynecology·2026
Same journal

Complex benign gynecology in perimenopause: current evidence and future directions.

Current opinion in obstetrics & gynecology·2026
Same journal

Role of insulin in female reproduction.

Current opinion in obstetrics & gynecology·2026
Same journal

Urinary tract involvement in endometriosis: current evidence and clinical insights into navigating diagnosis and management.

Current opinion in obstetrics & gynecology·2026
Same journal

Updates in ultrasound imaging of adenomyosis and clinical impacts.

Current opinion in obstetrics & gynecology·2026
See all related articles

In vitro fertilization is not cost-effective for unexplained infertility as a first-line treatment. However, it may be a cost-effective option for polycystic ovarian syndrome resistant to clomiphene citrate.

Area of Science:

  • Reproductive medicine
  • Health economics

Background:

  • Increasing demand for healthcare services necessitates economic evaluations of interventions.
  • Infertility treatments require careful consideration of cost-effectiveness.

Purpose of the Study:

  • To evaluate the cost-effectiveness of in-vitro fertilization (IVF) compared to other treatments for unexplained infertility and clomiphene citrate-resistant polycystic ovarian syndrome (PCOS).

Main Methods:

  • Comparative economic evaluation of different infertility treatment pathways.
  • Analysis of cost-effectiveness for unexplained infertility and clomiphene citrate-resistant PCOS.

Main Results:

  • In-vitro fertilization is not a cost-effective first-line treatment for unexplained infertility when compared to ovarian stimulation with intrauterine insemination.

Related Experiment Videos

  • In-vitro fertilization may be a cost-effective treatment option for patients with clomiphene citrate-resistant polycystic ovarian syndrome.

    • Conclusions:

    • Ovarian stimulation and intrauterine insemination are more cost-effective first-line treatments for unexplained infertility.
    • In-vitro fertilization presents a potential cost-effective strategy for specific cases of clomiphene citrate-resistant PCOS.